Stay updated on PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Sign up to get notified when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.

Latest updates to the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page
- Check4 days agoChange DetectedNo additions or deletions detected on the page. The observed changes appear to be routine metadata updates (e.g., last update timestamps) rather than substantive edits to study content.SummaryDifference0.5%

- Check11 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now includes a government-funding lapse notice and a new v3.2.0 update, replacing the old v3.1.0 tag.SummaryDifference4%

- Check40 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check54 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed, representing a minor UI change.SummaryDifference0.2%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check68 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location related to stomach cancer and its associated neoplasms, while several previous terms and resources have been removed.SummaryDifference3%

Stay in the know with updates to PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.